Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.
Location: United States, California, San Francisco
Total raised: $505M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Terra Magn... | terramagnu... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Timefolio ... | timefolioc... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.12.2024 | Series D | $115M | - |
| 10.01.2022 | - | $190M | - |
| 28.02.2019 | - | $200M | - |
Mentions in press and media 20
| Date | Title | Description |
| 08.01.2025 | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing By ReutersJanuary 7, 202511:00 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The Nasdaq logo is displayed at the Nasdaq Mark... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D | Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D. The round was co-led by investors Frazier Life Sciences and Deep Track Capital, with Janus Henderson In... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 12.01.2022 | Citadel Securities forms an unlikely partnership for its next big move | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Yesterday Sequoia Capital and Paradigm shared they had invested nearly $1.2 billion into Citadel ... |
| 10.01.2022 | Maze Therapeutics navigates $190M financing round as it plots course to the clinic | Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001, make a clinical debut. Maze wrapped up the fundraising round on Monday. Alongside news of the raise, the company ... |
| 10.01.2022 | Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases | Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced a $190 million financing led by Matrix Capital Management with participation from General Catalyst, a16z Bio+Health, Woodline Partners, ... |
| 10.01.2022 | Maze Therapeutics Announces $190M Financing | SOUTH SAN FRANCISCO, CA, Maze Therapeutics, a precision medicines startup, announced a $190 million financing led by Matrix Capital Management. >> Click here for more funding data on Maze Therapeutics >> To export Maze Thera... |
| 10.01.2022 | Maze Therapeutics navigates $190M financing round as it plots course to the clinic | Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001, make a clinical debut. sponsored by somalogic The power of the SomaScan®Assay is now available in panels Panels t... |
Show more